1

SK Life Science Introduction

2008. June

2

SK holdings SK Chemicals

Life Science Biz Life Science Division

Revenue: $ 848 MMEmployee > 300

Revenue: $ 1.2 B.Employee > 1,150

Life Science Business is outset for the growth drive in the future

Life Science in SK Group

SK Group

1) E&P: Exploration & Production

Holding company in SK Croup Fine Chemicals,

Life Science

New Drug Development

Custom Manufacturing Service

Drug development & Marketing

(Korean and Asian Market)

3

As of July 1st 2007, SK Corporation was divided into two companies, SK Energy and SK Holdings Ltd, and Life Science biz becomes a part of SK Holdings

Previous Structure New Structure

•SK Corporation had various operating divisions and held many subsidiary companies

•Reorganize as a holding company and 8 operating companies

•SK Life Science stays with holding company as one operating division

SK Corp.

SKTelecom

SKNetworks

OtherSubsidiaries

SK Holdings

SKTelecom

SKNetworks

OtherSubsidiaries

Purpose ofReorganization

Maximizing Management Efficiency Enhancing OverallShareholder Value

Solidifying Corporate Governance

Resolving the Issue of Under-valuation

SKEnergy

Life Science

Oil Refinery

E&P Lubri-cants

Chemicals

Life Science

SK Life Science

4

SK Life Science Biz.SK Life Science Biz.

Organization

* CMS: Custom Manufacturing Service

Discovery Lab.

Drug Preclinical Research Lab.

R&D Planning Team

New Jersey R&D Center

Shanghai R&D Center

Life Science Strategy Team

Process R&D Lab.

CMS Production Team

Marketing Team(New Jersey)

Seoul, Korea

Daejeon, Korea

Shanghai, China

New Jersey, USA

CMS Business(CMS 사업부 )

Drug Development Center( 신약개발사업부 )

Drug Development Center

6

KOREA

[Seoul]

Strategic Planning Licensing Out

[LSRDP 1)]

R&D Planning Licensing In Drug Discovery Early Preclinical Stud-ies Formulation Studies Intellectual Properties

USA

[New Jersey]

Advanced Preclinical Studies Clinical Studies in USA Regulatory Affairs in USA

CHINA

[Shanghai]

Drug discovery Market research in China

1) LSRDP: Life Science R&D Park

Drug Development Center

Role & Responsibility

7

1993

1996 1998

1999 2000

Start Pharmaceutical re-search in New Jersey, US and Daejeon, Korea focus-ing on CNS area

IND Approval for YKP10A,an antidepressant, from U.S. FDA

IND Approval for YKP509,an anticonvulsant, from U.S. FDA

Licensing Out to J&J (YKP10A)

Licensing Outto J&J (YKP509)

IND Approval for YKP1358,an Antipsychotic, from U.S. FDA

2003 2005

IND Approval for YKP3089,an anxiolytic, from U.S. FDA(currently at POC entering)

Establish Shanghai Drug Dev. Center

2002

The first Korean company to obtain IND approval from U.S. FDA

Licensing Out to Johnson & Johnson (CNS field)

Developing globally competitive new drug pipeline

2007

New IND expected

History

8

• Neuropathic Pain• Parkinson

Metabolicdiseases

CNS

• Obesity• Diabetes

• Epilepsy• Depression• Schizophrenia

DDS

• Transdermal• Controlled release• Intranasal Technology

R&D Areas

Successful track records in CNS drug discovery• Epilepsy, Depression, Schizophrenia, Neuropathic pain and Parkinson etc.

Expansion toward Metabolic diseases• Obesity, Diabetes and Osteoporosis

CV • Restenosis

9

DDS

Pipeline Status

Metabolic

CV

CNS By J&J

Compound for DES

Obesity

Diazepam Nasal spray

Pain (target based)

Parkinson Disease

Schizophrenia/Anxiety

Depression(SNDRI)

IBS

Neuropathic Pain

Schizophrenia (YKP1358)

Epilepsy/Anxiety/NP (YKP3089)

Depression (YKP10A)

Epilepsy(YKP509)

Planning IND & Phase I in 2008

Discov-ery

Lead Preclini-cal

Phase I Phase II Phase III

Partnering Alliance- Clinical Study expected in May, 2008

Narcolepsy, Drug addiction (Ready to IND)

on-going Preclinical studies w/ active enantiomer (YKP1447)

CMS Business

11

KOREA

[Seoul]

Planning

[LSRDP 1)]

Production

Process Development

QC/QA

USA

[New Jersey]

Marketing

Market Research

Customer Relationship

CHINA

[Shanghai]

Process Development

Biz Development

Raw Material Purchasing

CMS Business

Role & Responsibility

1) LSRDP: Life Science R&D Park

121) GMP (Good Manufacturing Practice)

Overview

Customers•Global Major Pharmaceutical Companies Pfizer, Roche, Bristol-Meyers-Squibb, Schering Plough, Novartis, GSK, J&J, etc.

Technology•Catalytic Processes, Continuous Reaction Technologies•Enzymatic technology•Conventional Organic Synthesis

Products & Services

•GMP Intermediates and API (End of 2007)•Process development and DMF support for customers

– Catalytic and Continuous Processes– Co-Work and DMF support

History & Location

•Operation since 2000 based on R&D capabilities•Production Plants and R&D in Daejeon, Korea•Marketing in NJ, USA

SK CMS provides custom manufacturing service to the global major pharma companies based on the innovative technological and production capabilities with a cGMP complied quality system

13

Quality System

Plant Operation based upon cGMP & ICH Q7A

• Quality Management System

• Material Control System

• Facilities & Equipment System

• Production & In-Process Control System

• Laboratory Control System

Quality Assurance based on Quality Management Systems

• ’98 ~’01 GSK• ’02 ~’03 Roche, Novartis, Pfizer• ’04 ~’05 Pfizer, GSK, BMS, Lonza• ’06 Pfizer, BMS (Approved for cGMP Intermediate Production)• Current Preparation of API Production and DMF Filing for New Drug

Audits and Approval by Many Customers

14

`08 년 하반기 신입 사원 채용

모집분야 주요업무 모집인원

Process Chemist

• 유기합성 기술을 활용한 신약 후보물질 및 관련 중간체 제조 공정 개발 연구 0 명

Process Engi-neer

• 신규 촉매 개발 , 신규 연속공정 개발 업무 0 명

Thank you